Form 4 for ACAD ACADIA PHARMACEUTICALS INC

Accepted 2023-10-06 00:00:00 ET · period of report 2023-10-05 · accession 0001209191-23-052389 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-10-06	2023-10-05	ACAD	DAVIS STEPHEN	CEO, Dir	M - OptEx	—	+104.0K	140.7K	+283%	—
D	2023-10-06	2023-10-06	ACAD	DAVIS STEPHEN	CEO, Dir	S - Sale+OE	$21.96	-51.6K	89.1K	-37%	-$1.13M
D	2023-10-06	2023-10-06	ACAD	DAVIS STEPHEN	CEO, Dir	M - OptEx	$0.00	-104.0K	173.3K	-37%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-10-05	M	A	103,999	—	140,694	D	—	—	(F1) Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. (F2) Includes 1,594 shares acquired by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan on May 15, 2023.
2	Common	Common Stock	2023-10-06	S	D	51,563	$21.96	89,131	D	—	—	(F3) The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
3	Derivative	Restricted Stock Units	2023-10-06	M	D	103,999	$0.00	173,332	D	— · — to —	103,999 Common Stock	(F1) Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. (F4) Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.